Vertex Pharmaceuticals (VRTX) Free Cash Flow (2009 - 2026)

Vertex Pharmaceuticals has reported Free Cash Flow for 18 years, with the latest figure at $1.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow rose 66.37% year-over-year to $1.3 billion; the trailing twelve-month figure through Mar 2026 stood at $3.7 billion (up 396.75% YoY), and the FY2025 full-year result was $3.2 billion, up 504.13% from the prior year.
• Free Cash Flow for Q1 2026 stood at $1.3 billion, up from $348.6 million in the prior quarter.
• The five-year high for Free Cash Flow was $1.3 billion in Q3 2024, with the low at -$3.8 billion in Q2 2024.
• Average Free Cash Flow over 5 years is $644.7 million, with a median of $927.4 million recorded in 2025.
• Year-over-year, Free Cash Flow soared 535.3% in 2022 and plunged 455.66% in 2024.
• Tracing VRTX's Free Cash Flow over 5 years: stood at $1.0 billion in 2022, then plunged by 83.11% to $176.5 million in 2023, then soared by 178.75% to $492.0 million in 2024, then retreated by 29.15% to $348.6 million in 2025, then jumped by 271.4% to $1.3 billion in 2026.
• The last three Free Cash Flow figures came in at $1.3 billion (Q1 2026), $348.6 million (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.

Peer Comparison